In the current work, we present a patient with metastatic cholangiocarcinoma harboring a novel FGFR2–CLIP1 gene fusion who demonstrated a partial response followed by disease progression while on treatment with the FGFR-selective kinase inhibitor, INCB054828. This evidence concerns the gene FGFR2 and cholangiocarcinoma.